Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00072722 | Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | PHASE2 | COMPLETED | 36 | — | — | Sep 1, 2003 | Apr 1, 2005 | Dec 19, 2006 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| CC-4047 | DRUG | - |
Inclusion Criteria: * Understand and voluntarily sign an informed consent form * Adult male subjects, age 18 or older at the time of signing the informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Histologically confirmed adenocarcinoma of the prosta...